Pennant group chief clinical officer sells $53,699 in stock
Jason Paul Steik, Pennant Group's Chief Clinical Officer, sold 1,394 shares of the company's stock on August 6, 2026. The transaction, priced at $38.522 per share, amounted to $53,699. At the time of sale, PNTG shares were trading close to $39.32, marking a substantial 55.66% return over the past year and a 39.68% gain year-to-date.
Post-sale, Mr. Steik retains 15,106 shares of Pennant Group, Inc. common stock. This information was filed with the Securities and Exchange Commission via a Form 4. InvestingPro's analysis suggests the stock is currently overvalued, with a P/E ratio of 42.92. For those interested in further insights, the Pro Research Report offers 7 additional ProTips and detailed analysis.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
